Qiagen has been granted a patent for methods and compositions that enable the detection and monitoring of Lyme disease. The approach involves using synthetic peptides derived from Borrelia proteins to stimulate T-cell responses in whole blood samples, aiding in diagnosis and treatment efficacy assessment. GlobalData’s report on Qiagen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Qiagen, Nucleoside chemical synthesis was a key innovation area identified from patents. Qiagen's grant share as of July 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Method for detecting and monitoring lyme disease using peptides
The granted patent US12066436B2 outlines a method for detecting Lyme disease and monitoring treatment efficacy in subjects. The method involves in vitro analysis of biological samples containing T-cells and antigen-presenting cells. Initially, a biological sample is contacted with a peptide composition that includes specific Borrelia T-cell epitopes. This mixture is incubated to stimulate a T-cell immune response, which is then measured. An increase in the T-cell immune response indicator, compared to a control level, suggests the presence of a Borrelia infection. The peptide composition can include various isolated peptides from FlaB, DbpB, p66, and OspC, each with defined amino acid sequences or variants.
Additionally, the method allows for monitoring treatment efficacy by comparing immune response indicators from samples taken before and after treatment. A decrease in the immune response indicator post-treatment indicates successful treatment. The patent specifies that the biological samples can include whole blood, cerebrospinal fluid, or synovial fluid, and the immune response can be measured through various cytokines, including interferon-gamma (IFN-?). The method is applicable to infections caused by pathogenic Borrelia species, such as Borrelia burgdorferi, and outlines the use of antibiotics for treatment. This innovative approach aims to enhance the diagnosis and management of Lyme disease through precise immunological assessments.
To know more about GlobalData’s detailed insights on Qiagen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
